MOUNJARO SOLUTION

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

TIRZEPATIDE

Disponibbli minn:

ELI LILLY CANADA INC

Kodiċi ATC:

A10BX16

INN (Isem Internazzjonali):

TIRZEPATIDE

Dożaġġ:

7.5MG

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

TIRZEPATIDE 7.5MG

Rotta amministrattiva:

SUBCUTANEOUS

Unitajiet fil-pakkett:

100

Tip ta 'preskrizzjoni:

Prescription

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0164301003; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2022-11-24

Karatteristiċi tal-prodott

_ _
_MOUNJARO (tirzepatide injection) _
_Page 1 of 45_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MOUNJARO™
tirzepatide injection
Solution, 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL,
12.5 mg/0.5 mL,
15 mg/0.5 mL, in a single-dose prefilled pen for subcutaneous use
Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like
Peptide-1 (GLP-1)
Receptor Agonist
Antihyperglycemic Agent
Eli Lilly Canada Inc.
Exchange Tower
130 King Street West, Suite 900
P.O. Box 73
Toronto, Ontario
M5X 1B1
1-888-545-5972
www.lilly.ca
Date of Initial Authorization:
NOV 23, 2022
Submission Control Number: 259103
MOUNJARO is a trademark owned by or licensed to Eli Lilly and Company,
its subsidiaries or
affiliates.
_ _
_MOUNJARO (tirzepatide injection) _
_Page 2 of 45_
RECENT MAJOR LABEL CHANGES
None at time of authorization
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.....................................................................................
2
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................
4
1
INDICATIONS..............................................................................................................
4
1.1
Pediatrics
...........................................................................................................
4
1.2
Geriatrics............................................................................................................
4
2
CONTRAINDICATIONS
...............................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS
BOX...................................................... 5
4
DOSAGE AND ADMINISTRATION
..............................................................................
5
4.1
Dosing Considerations
...........